口服卵泡刺激素受体激动剂对人颗粒细胞的影响不同于重组人卵泡刺激素
基础研究纳入41例不孕患者(8例卵巢储备正常、17例高龄、12例多囊卵巢综合征、4例合并诊断),比较口服FSHR变构激动剂TOP5300与重组人FSH对黄素化颗粒细胞雌二醇生成、类固醇合成基因表达及FSHR膜定位的影响。TOP5300在各组均刺激雌二醇生成,重组人FSH在卵巢储备正常组更有效、在高龄和多囊卵巢综合征组无效;TOP5300诱导的StAR和CYP19A1表达在高龄和卵巢储备正常组低于多囊卵巢综合征组。
要点
- TOP5300在卵巢储备正常、高龄和多囊卵巢综合征患者颗粒细胞中均刺激雌二醇生成。
- 重组人FSH在卵巢储备正常组更有效,但在高龄和多囊卵巢综合征组无效。
- TOP5300诱导的StAR和CYP19A1表达在高龄和卵巢储备正常组低于多囊卵巢综合征组。
核心结论
- TOP5300似乎比重组人FSH更能刺激多囊卵巢综合征患者黄素化颗粒细胞雌二醇生成和类固醇合成基因表达,相对于高龄和卵巢储备正常患者。
- FSHR在细胞膜的定位似乎不是TOP5300或重组人FSH刺激类固醇合成基因表达和雌二醇生成的限速步骤。
研究设计与样本
- 基础科学研究,采用临床前FSHR变构激动剂。
- 在大学医院附属单一学术生育诊所招募不孕患者,经机构审查委员会批准方案建立41例原代颗粒细胞培养,其中8例卵巢储备正常、17例高龄、12例多囊卵巢综合征、4例合并诊断。
- 原代黄素化颗粒细胞培养分别用重组人FSH、TOP5300或溶剂处理。
主要发现
- TOP5300在卵巢储备正常、高龄和多囊卵巢综合征患者中均持续刺激雌二醇生成。
- 重组人FSH在卵巢储备正常患者黄素化颗粒细胞中为更强配体,但在高龄或多囊卵巢综合征患者细胞中无效。
- FSHR质膜定位最低见于高龄患者,多囊卵巢综合征患者细胞中更丰富,最高见于卵巢储备正常患者。
- TOP5300相对于重组人FSH未影响任何患者组的FSHR定位。
- TOP5300在卵巢储备正常、高龄和多囊卵巢综合征患者合并细胞中刺激StAR和CYP19A1表达更明显,重组人FSH无法刺激多囊卵巢综合征患者细胞的StAR和芳香化酶(CYP19A1)表达;TOP5300诱导的高龄和卵巢储备正常患者StAR和CYP19A1 mRNA表达持续低于多囊卵巢综合征患者细胞。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether TOP5300, a novel oral follicle-stimulating hormone (FSH) receptor (FSHR) allosteric agonist, elicits a different cellular response than recombinant human FSH (rh-FSH) in human granulosa cells from patients undergoing in vitro fertilization. DESIGN: Basic science research with a preclinical allosteric FSHR agonist. SETTING: University hospital. PATIENT(S): Patients with infertility at a single academic fertility clinic were recruited under an Institutional Review Board-approved protocol. Primary granulosa cell cultures were established for 41 patients, of whom 8 had normal ovarian reserve (NOR), 17 were of advanced reproductive age (ARA), 12 had a diagnosis of polycystic ovary syndrome (PCOS), and 4 had a combination of diagnoses, such as ARA and PCOS. INTERVENTION(S): Primary granulosa-lutein (GL) cell cultures were treated with rh-FSH, TOP5300, or vehicle. MAIN OUTCOME MEASURE(S): Estradiol (E2) production using enzyme-linked immunosorbent assay, steroid pathway gene expression of StAR and aromatase using quantitative polymerase chain reaction, and FSHR membrane localization using immunofluorescence were measured in human GL cells. RESULT(S): TOP5300 consistently stimulated E2 production among patients with NOR, ARA, and PCOS. Recombinant FSH was the more potent ligand in GL cells from patients with NOR but was ineffective in cells from patients with ARA or PCOS. The lowest level of FSHR plasma membrane localization was seen in patients with ARA, although FSHR localization was more abundant in cells from patients with PCOS; the highest levels were present in cells from patients with NOR. The localization of FSHR was not affected by TOP5300 relative to rh-FSH in any patient group. TOP5300 stimulated greater expression of StAR and CYP19A1 across cells from all patients with NOR, ARA, and PCOS combined, although rh-FSH was unable to stimulate StAR and aromatase (CYP19A1) expression in cells from patients with PCOS. TOP5300-induced expression of StAR and CYP19A1 mRNA among patients with ARA and NOR was consistently lower than that observed in cells from patients with PCOS. CONCLUSION(S): TOP5300 appears to stimulate E2 production and steroidogenic gene expression from GL cells more than rh-FSH in PCOS, relative to patients with ARA and NOR. It does not appear that localization of FSHR at cell membranes is a limiting step for TOP5300 or rh-FSH stimulation of steroidogenic gene expression and E2 production.
引用
- Guner JZ, Monsivais D, Yu H, et al. Oral follicle-stimulating hormone receptor agonist affects granulosa cells differently than recombinant human FSH. Fertil Steril. 2023. PMID: 37532169. doi:10.1016/j.fertnstert.2023.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。